Royalty Pharma (RPRX) Non-Current Debt (2019 - 2026)

Royalty Pharma has reported Non-Current Debt for 8 years, with the latest figure at $9.0 billion in Q1 2026.

• Quarterly Non-Current Debt rose 35.32% year-over-year to $9.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.0 billion (up 35.32% YoY) and the FY2025 annual result came in at $9.0 billion, up 17.58% from the prior year.
• Non-Current Debt was little changed at $9.0 billion in Q1 2026 per RPRX's latest filing, from $9.0 billion in the prior quarter.
• Over five years, Non-Current Debt peaked at $9.0 billion in Q1 2026 and troughed at $6.1 billion in Q4 2022.
• A 5-year average of $7.1 billion and a median of $7.1 billion in 2022 frame the typical range for Non-Current Debt.
• The sharpest annual moves came in 2024 and 2026: Non-Current Debt dropped 13.79% in 2024, then soared 35.32% in 2026.
• Over 5 years, Non-Current Debt stood at $6.1 billion in 2022, then advanced by 0.27% to $6.1 billion in 2023, then gained by 24.08% to $7.6 billion in 2024, then increased by 17.58% to $9.0 billion in 2025, then increased by 0.06% to $9.0 billion in 2026.
• According to Business Quant data, Non-Current Debt over the past three periods registered $9.0 billion, $9.0 billion, and $8.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.